Medical consumption upgrade, this market will usher in explosive growth!

In recent years, with the promotion of policies such as restriction orders, drug tenders and medical insurance charges, the growth rate of revenue and profits of China's chemical agent industry has gradually slowed down.
Due to the large number of domestic chemical preparation production enterprises, and the market competition is more intense, the industry believes that in the context of the pharmaceutical policy of volume procurement and encouraging the development of new drugs, innovative drugs and generic drugs with high barriers and high value will become the direction of industry development, while the new preparation industry may usher in development opportunities.
is a new preparation? It is understood that traditional preparations include intravenous preparations, intramuscular injections, oral tablets, capsules and so on.
And the scope of innovative preparations generally refers to the use of modern preparation technology (including slow release agents, liposomes, lipid microspheres, hydrogels and sub-sensitive gel transdermission pastes, fat milk, nanoparticles, inhalation agents, implants, etc.), the drug is dispersed in a special structure system, thus different from the traditional method of administration of drugs.
the new preparation takes less money and time than the compound's new drug.
there are reports that the average cost of developing a new compound drug is $500 million to $1 billion, which takes 10 to 12 years, while the development of a new drug for a new drug takes only $0.5 billion, with an average time of only 3 to 4 years.
At the same time, innovative agents have a higher success rate at all stages of new drug development than new compounds and biologics: from Phase I clinical to approved market, the success rate is more than three times that of new compounds, about twice that of biological drugs.
, innovative agents may have two characteristics: high yield and long life cycle.
, for example, has led to rapid market growth as a result of improvements in Johnson and Johnson's Lipeone range.
2015, Johnson and Johnson sold more than $2.5 billion in the U.S. with just three products: Risperdal Consta, Invega and Invega Sustenna.
experts believe that with the continuous upgrading of domestic pharmaceutical consumption, the use of new preparations will become a trend, the future of China's new preparation market will usher in explosive growth, mainly based on the following two reasons.
, data show that the global compound annual growth rate of new preparations over the past decade has exceeded 10%, higher than the average growth level of the pharmaceutical industry.
, but in terms of China's new preparation industry, the uity rate is less than 5%, far below the global average, so there is broad prospects for development.
currently on the domestic innovative preparation industry enterprises, Hengrui Pharmaceuticals in the long-acting protein preparations, ADC drugs, carrier drugs in the positive layout.
, Changchun High-new, Shuangyi Pharmaceuticals, Stone Pharmaceutical Group and Qilu Pharmaceuticals and a number of domestic pharmaceutical companies are also expanding the layout.
, the tumor drug albumin yew alcohol is one of the highlights of the product, the domestic Hengrui medicine and stone medicine has been approved.
It is worth mentioning that, at the time of the winning bid in the second batch, the new base company selected albumin yew alcohol was disqualified from collection, by the stone pharmaceutical group Euro-Italian Pharmaceuticals, Hengrui Pharmaceuticals according to the selected price, the replacement supply was originally supplied by the new base company provinces.
At present, the domestic albumin yew alcohol market size of about 1.4 billion yuan, the new base company only about 29% of the market share, Stone Pharmaceutical Group, Hengrui Pharmaceuticals accounted for 50%, 20% of the market share.
industry believes that this action or accelerate generic drug replacement research.
the other hand, with the aging of the population, the improvement of living standards, the strengthening of health awareness, the continuous improvement of the social security system and the continuous development of medical technology, the demand for pharmaceutical preparations continues to expand.
2019, China's pharmaceutical preparation industry market size of about 1.21 trillion yuan, an increase of 8.04 percent over 2018, the industry's rapid growth rate.
In the context of the expanding market size of pharmaceutical preparations, the pharmaceutical industry's long-term "heavy raw materials, light preparations" development model is expected to change, in the development of raw materials industry at the same time, the status of the preparation industry will be enhanced, further breaking China's new preparations, new accessories and preparations of new technology market is almost monopolized by foreign companies.
.